| Indication |
For treatment of osteoarthritis and rheumatoid arthritis. |
| Pharmacodynamics |
Piroxicam is in a class of drugs called nonsteroidal
anti-inflammatory drugs (NSAIDs). Piroxicam works by reducing hormones
that cause inflammation and pain in the body. Piroxicam is used to
reduce the pain, inflammation, and stiffness caused by rheumatoid
arthritis and osteoarthritis. |
| Mechanism of action |
The antiinflammatory effect of Piroxicam may result from the
reversible inhibition of cyclooxygenase, causing the peripheral
inhibition of prostaglandin synthesis. The prostaglandins are produced
by an enzyme called Cox-1. Piroxicam blocks the Cox-1 enzyme, resulting
into the disruption of production of prostaglandins. Piroxicam also
inhibits the migration of leukocytes into sites of inflammation and
prevents the formation of thromboxane A2, an aggregating agent, by the
platelets. |
| Absorption |
Well absorbed following oral administration. |
| Volume of distribution |
|
| Protein binding |
Not Available |
| Metabolism |
Renal |
| Route of elimination |
Piroxicam and its biotransformation products are excreted in urine
and feces, with about twice as much appearing in the urine as in the
feces. Approximately 5% of a piroxicam dose is excreted unchanged.
However, a substantial portion of piroxicam elimination occurs by
hepatic metabolism. Piroxicam is excreted into human milk. |
| Half life |
30 to 86 hours |
| Clearance |
Not Available |
| Toxicity |
Symptoms of overdose include drowsiness, nausea, stomach pain, and/or vomiting. |
